Unknown

Dataset Information

0

Cell-free DNA alterations in the AR enhancer and locus predict resistance to AR-directed therapy in patients with metastatic prostate cancer.


ABSTRACT:

Purpose

Cell-free DNA (cfDNA) and circulating tumor cell (CTC) based liquid biopsies have emerged as potential tools to predict responses to androgen receptor (AR)-directed therapy in metastatic prostate cancer. However, due to complex mechanisms and incomplete understanding of genomic events involved in metastatic prostate cancer resistance, current assays (e.g. CTC AR-V7) demonstrate low sensitivity and remain underutilized. The recent discovery of AR enhancer amplification in >80% of metastatic patients and its association with disease resistance presents an opportunity to improve upon current assays. We hypothesized that tracking AR/enhancer genomic alterations in plasma cfDNA would detect resistance with high sensitivity and specificity.

Methods

We developed a targeted sequencing and analysis method as part of a new assay called Enhancer and neighboring loci of Androgen Receptor Sequencing (EnhanceAR-Seq). We applied EnhanceAR-Seq to plasma collected from 40 patients with metastatic prostate cancer treated with AR-directed therapy to monitor AR/enhancer genomic alterations and correlate these events with therapy resistance, progression-free survival (PFS) and overall survival (OS).

Results

EnhanceAR-Seq identified genomic alterations in the AR/enhancer locus in 45% of cases, including a 40% rate of AR enhancer amplification. Patients with AR/enhancer alterations had significantly worse PFS and OS than those without (6-month PFS: 30% vs. 71%, P=0.0002; 6-month OS: 59% vs. 100%, P=0.0015). AR/enhancer alterations in plasma cfDNA detected 18 of 23 resistant cases (78%) and outperformed the CTC AR-V7 assay which was also run on a subset of patients.

Conclusion

cfDNA-based AR locus alterations, including of the enhancer, are strongly associated with resistance to AR-directed therapy and significantly worse survival. cfDNA analysis using EnhanceAR-Seq may enable more precise risk stratification and personalized therapeutic approaches for metastatic prostate cancer.

SUBMITTER: Dang HX 

PROVIDER: S-EPMC7446541 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cell-free DNA alterations in the <i>AR</i> enhancer and locus predict resistance to AR-directed therapy in patients with metastatic prostate cancer.

Dang Ha X HX   Chauhan Pradeep S PS   Ellis Haley H   Feng Wenjia W   Harris Peter K PK   Smith Grace G   Qiao Mark M   Dienstbach Katherine K   Beck Rachel R   Atkocius Andrew A   Qaium Faridi F   Luo Jingqin J   Michalski Jeff M JM   Picus Joel J   Pachynski Russell K RK   Maher Christopher A CA   Chaudhuri Aadel A AA  

JCO precision oncology 20200618


<h4>Purpose</h4>Cell-free DNA (cfDNA) and circulating tumor cell (CTC) based liquid biopsies have emerged as potential tools to predict responses to androgen receptor (AR)-directed therapy in metastatic prostate cancer. However, due to complex mechanisms and incomplete understanding of genomic events involved in metastatic prostate cancer resistance, current assays (e.g. CTC AR-V7) demonstrate low sensitivity and remain underutilized. The recent discovery of <i>AR</i> enhancer amplification in >  ...[more]

Similar Datasets

| S-EPMC4452946 | biostudies-literature
| S-EPMC7165042 | biostudies-literature
| S-EPMC10867901 | biostudies-literature
| S-EPMC8197232 | biostudies-literature
| S-EPMC8452729 | biostudies-literature
| S-EPMC5122410 | biostudies-literature
| S-EPMC5097690 | biostudies-literature
| S-EPMC10053078 | biostudies-literature
| S-EPMC7943793 | biostudies-literature
| S-EPMC10441451 | biostudies-literature